Arca
Skip to content
Tools
Tools

Microscopic polyangiitis

Drug research and approvals for microscopic polyangiitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 10 studies of microscopic polyangiitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 10
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 10 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • RituximabB-lymphocyte antigen CD20 binding agent
  • AvacopanC5a anaphylatoxin chemotactic receptor antagonist

Phase 3 4

Phase 2 4

How its trials ended

54 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 15 whose ending is known, 33% met their primary endpoint, 20% missed it and 47% stopped early.

  • Completed, result not reported2037%
  • Ongoing1120%
  • Status unknown815%
  • Met its primary endpoint59%
  • Missed its primary endpoint36%
  • Stopped: other or unclear36%
  • Stopped: funding24%
  • Stopped: enrollment or feasibility12%
  • Stopped: sponsor or business decision12%

FDA orphan designations

Approved first, then open designations, newest first
Oct 7, 2021TavneosAs an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis…ChemoCentryx, Inc.Approved
Sep 27, 2019RituxanRITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with…Genentech, Inc.Approved
Apr 19, 2011RituxanFor the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and…Genentech, Inc.Approved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.